About Us
We are a Canadian-based technology company engaged in the development and commercialization of products that prevent and remove microbial biofilms.
About Kane
The Company was formed in 2001 to study the genetic mechanisms of biofilm formation, which has led to the discovery of novel compounds that inhibit or disrupt biofilms.
Mission Statement
To improve Human and Animal welfare through the research and development of solutions to biofilms and anti-microbial resistance.
Vision
To be recognized as THE Biofilm company. We aim to discover, develop and commercialize technologies that resolve the biofilm problem and improve quality of life.
Our Location
Kane Biotech’s offices and laboratories are located in the University of Manitoba Smartpark Innovation Hub. It includes two independent analytical laboratories and three independent and well-equipped microbiology suites.
Click on the Matterport links to take an immersive 3D virtual tour of Kane Biotech’s offices and laboratories.
Smartpark is a world-class research and technology park adjacent to the University of Manitoba, the most research-intensive university campus in the Province of Manitoba. Smartpark’s vision is “Building a Community of Innovators” on the doorstep of the University of Manitoba. Smartpark continues to advance its mission, vision and mandate to become a symbol of science, innovation and advanced technology at the University of Manitoba while also playing a wider role within the regional knowledge-based economy.
Corporate Strategy
Kane Biotech is a discovery and development company focused on novel products that prevent and disperse bacterial biofilms. Kane was formed to translate these discoveries into innovative solutions for human and animal health, as well as industrial applications. Kane’s commercial strategy is to create value for shareholders through the establishment of global partnerships and licensing agreements with leading companies to commercialize our innovations. To de-risk our technologies towards commercialization we will conduct more advanced clinical studies and achieve regulatory and safety certifications.
Discovery
- Internal discovery of novel technologies that inhibit and disperse biofilms and control microbial infections
- In-licensing of exclusive, novel biofilm technologies: University of Toronto and University of Manitoba – Canada, Rutgers University – USA
Development
- Develop and test prototypes
- Conduct pre-clinical performance tests
- Examine durability, stability and biocompatibility
- Joint development agreements or partner assisted clinical trials
Commercialization
- Partnerships or licensing agreements are developed with leading companies to manufacture and commercialize products.
- Test products for market acceptance and create brands for market launch.
Our Team
Meet the people behind Kane Biotech.
Management Team
-
Dr. Robert Huizinga, PhD RN, CNeph(C)
Interim Chief Executive Officer
Dr. Huizinga is currently the principal of Reformation Consulting Services. He was formerly the Executive Vice-President of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and led the clinical development of voclosporin which had first year sales of $100 million USD. Prior to that, Dr. Huizinga was the Vice President of Clinical Affairs for Isotechnika Inc (TSV:ISA), and was a clinical investigator at the University of Alberta. Dr. Huizinga holds a PhD in Organizational Leadership, a Masters in Clinical Epidemiology, holds a Nephrology certification and is a member of Sigma Theta Tau. He holds a certificate in leadership from EQUIP Leadership.
-
Ray Dupuis
Chief Financial Officer
Ray Dupuis joined Kane Biotech as Chief Financial Officer in September 2017. Mr. Dupuis has more than 25 years of financial leadership experience across a broad range of industries including 15 years at a rapidly growing public biotechnology company and brings to the organization considerable financial acumen and strategic skills. Mr. Dupuis is a Chartered Professional Accountant (CPA, CGA) and possesses Bachelor of Science (Biology), Bachelor of Arts (Administrative Studies) and Master of Business Administration (Finance) degrees.
-
Lori Christofalos
Chief Quality Officer
Lori Christofalos joined Kane Biotech as VP, Quality & Compliance in August 2019. Ms. Christofalos has over 25 years of leadership experience in Quality, Compliance, Validation and Regulatory Affairs in regulated Pharma industry in both domestic and international domains. In addition to this she brings to the organization extensive knowledge of Strategic Planning and process development. Ms. Christofalos has served on Industry boards, is a member of ASQ and holds a Bachelor of Science (Chemistry) and a diploma in Bioengineering-Chemical Technology.
Board of Directors
-
Philip Renaud
Milan, Italy
Board Chair
Mr. Renaud is Chairman, CEO and President of Redecam Group, a global leader in providing highly engineered industrial air pollution control solutions. A graduate of Franklin College of Switzerland with a Bachelor of Arts in international financial management, Mr. Renaud has been instrumental in securing many private equity financings and has an extensive European and North American network. He is a past director and chairman of a number of publicly traded companies including Sierra Metals Inc.
-
Dr. Robert Huizinga, PhD RN, CNeph(C)
Interim Chief Executive Officer
Dr. Huizinga is currently the principal of Reformation Consulting Services. He was formerly the Executive Vice-President of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and led the clinical development of voclosporin which had first year sales of $100 million USD. Prior to that, Dr. Huizinga was the Vice President of Clinical Affairs for Isotechnika Inc (TSV:ISA), and was a clinical investigator at the University of Alberta. Dr. Huizinga holds a PhD in Organizational Leadership, a Masters in Clinical Epidemiology, holds a Nephrology certification and is a member of Sigma Theta Tau. He holds a certificate in leadership from EQUIP Leadership.
-
Dr. John Coleman
Director
Dr. Coleman brings a wealth of scientific and business expertise to the board. Currently serving as the President and CEO of Avivo Biomedical Inc., a Vancouver-based biotech firm specializing in groundbreaking technologies facilitating the conversion of blood and organs into universally accepted types, thereby significantly improving the utilization of the existing pool of donors. Before his tenure at Avivo, Coleman co-founded Anandia Labs in 2013, growing it to become a leading cannabis testing and genetics company. Following Anandia’s acquisition by Aurora Cannabis in 2018, Coleman continued to lead analytical testing at Anandia until 2020.
-
Anne Greven
Director
Ms. Greven is currently Managing Director & Head of Loan Distribution Group at ING Capital LLC in NA. Prior to that, Ms. Greven held various Managing Director roles at Rabobank International & Rabo Securities Investment Banking, USA. Ms. Greven also serves on a few Boards including Whole & Free Foods LLC and Students for Senegal. She holds an MBA from Columbia Business School, BS from Montana State University and has completed executive educations programs at Harvard Business School and London Business School.
-
Shameze Rampertab
Director
Mr. Rampertab most recently served as Executive Vice President and CFO for Asensus Surgical, Inc. (NYSE American: ASXC), a robotic surgery company with intra-operative augmented intelligence. Prior to that Mr. Rampertab was Interim CEO, CFO and Corporate Secretary for Zomedica Pharmaceuticals Corp. (NYSE American: ZOM; TSXV: ZOM), a veterinary health company creating diagnostics and therapeutics. Mr. Rampertab also serves on the Board of Electro Metals and Mining Inc., an exploration and development metal deposit company, and is a past Board member of Zomedica. Before joining Zomedica, he served as CFO and Secretary at Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a thermal ablation medical device company. Prior to that he was CFO and Vice President of Finance for Intellipharmaceutics International Inc. (NASDAQ; IPCI; TSX:I), a specialty pharmaceutical company. In addition to significant experience in corporate leadership roles, his background also includes time spent as an investment banker and sell-side equity research analyst. Mr. Rampertab is a CPA, CA and also holds an MBA and BSc in Molecular Genetics and Molecular Biology.
-
Dr. David Kideckel
Director
Dr. David M. Kideckel, Ph.D., MBA, presently serves as Chief Financial Officer (CFO), and Board Director at Rakovina Therapeutics (TSX-V: RKV) (FSE: 7JO).
Dr. Kideckel has nearly two decades of experience in life sciences, capital markets, and corporate advisory, with a proven track record of assisting public and private healthcare companies scale their operations and unlock shareholder value. He is the Founder and Principal of the Kideckel Advisory Group Inc., which provides CFO, Chief Business Officer (CBO), and capital markets services to TSX- and Nasdaq-listed companies, as well as private corporations. He also serves as a Partner at Siskos & Associates, a full service professional accounting firm, and is Executive Chairman of Pharmadrug Inc (CNSX: PHRX).
Prior to his current roles, Dr. Kideckel served as Managing Director, Head of Life Sciences, and Senior Institutional Equity Research Analyst at ATB Capital Markets. His industry experience includes leadership positions at Johnson & Johnson Inc. and Alexion Pharmaceuticals (acquired by AstraZeneca PLC), where he supported strategic growth initiatives in drug development and commercialization.
Dr. Kideckel holds a Ph.D. in Neuroscience and Statistics from the University of Toronto’s Institute of Medical Science and an MBA from the Rotman School of Management.
Careers
Working at Kane
Kane Biotech is always looking for bright, talented, and hard working individuals to add to our high performing team.
If you would like the opportunity to work in an exciting and innovative biotech industry, send in your resume for possible future openings.